A citation-based method for searching scientific literature

Eytan M Stein, Courtney D DiNardo, Daniel A Pollyea, Amir T Fathi, Gail J Roboz, Jessica K Altman, Richard M Stone, Daniel J DeAngelo, Ross L Levine, Ian W Flinn, Hagop M Kantarjian, Robert Collins, Manish R Patel, Arthur E Frankel, Anthony Stein, Mikkael A Sekeres, Ronan T Swords, Bruno C Medeiros, Christophe Willekens, Paresh Vyas, Alessandra Tosolini, Qiang Xu, Robert D Knight, Katharine E Yen, Sam Agresta, Stephane de Botton, Martin S Tallman. Blood 2017
Times Cited: 638







List of co-cited articles
927 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Gail J Roboz, Jessica K Altman, Alice S Mims, Ronan Swords, Robert H Collins, Gabriel N Mannis, Daniel A Pollyea,[...]. N Engl J Med 2018
524
77

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Richard M Stone, Sumithra J Mandrekar, Ben L Sanford, Kristina Laumann, Susan Geyer, Clara D Bloomfield, Christian Thiede, Thomas W Prior, Konstanze Döhner, Guido Marcucci,[...]. N Engl J Med 2017
821
38

Genomic Classification and Prognosis in Acute Myeloid Leukemia.
Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger, Verena I Gaidzik, Peter Paschka, Nicola D Roberts, Nicola E Potter, Michael Heuser, Felicitas Thol, Niccolo Bolli,[...]. N Engl J Med 2016
28

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
Hartmut Döhner, Elihu Estey, David Grimwade, Sergio Amadori, Frederick R Appelbaum, Thomas Büchner, Hervé Dombret, Benjamin L Ebert, Pierre Fenaux, Richard A Larson,[...]. Blood 2017
28

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Gail J Roboz, Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Alice S Mims, Gabrielle T Prince, Jessica K Altman, Martha L Arellano, Will Donnellan, Harry P Erba,[...]. Blood 2020
90
31

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
Courtney D DiNardo, Brian A Jonas, Vinod Pullarkat, Michael J Thirman, Jacqueline S Garcia, Andrew H Wei, Marina Konopleva, Hartmut Döhner, Anthony Letai, Pierre Fenaux,[...]. N Engl J Med 2020
227
28

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Maria E Figueroa, Omar Abdel-Wahab, Chao Lu, Patrick S Ward, Jay Patel, Alan Shih, Yushan Li, Neha Bhagwat, Aparna Vasanthakumar, Hugo F Fernandez,[...]. Cancer Cell 2010
25

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
Alexander E Perl, Giovanni Martinelli, Jorge E Cortes, Andreas Neubauer, Ellin Berman, Stefania Paolini, Pau Montesinos, Maria R Baer, Richard A Larson, Celalettin Ustun,[...]. N Engl J Med 2019
263
25

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
Courtney D DiNardo, Keith Pratz, Vinod Pullarkat, Brian A Jonas, Martha Arellano, Pamela S Becker, Olga Frankfurt, Marina Konopleva, Andrew H Wei, Hagop M Kantarjian,[...]. Blood 2019
599
24

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
Michael D Amatangelo, Lynn Quek, Alan Shih, Eytan M Stein, Mikhail Roshal, Muriel D David, Benoit Marteyn, Noushin Rahnamay Farnoud, Stephane de Botton, Olivier A Bernard,[...]. Blood 2017
180
22

Acute Myeloid Leukemia.
Hartmut Döhner, Daniel J Weisdorf, Clara D Bloomfield. N Engl J Med 2015
20

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Jorge E Cortes, Florian H Heidel, Andrzej Hellmann, Walter Fiedler, B Douglas Smith, Tadeusz Robak, Pau Montesinos, Daniel A Pollyea, Pierre DesJardins, Oliver Ottmann,[...]. Leukemia 2019
197
20

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Wei Xu, Hui Yang, Ying Liu, Ying Yang, Ping Wang, Se-Hee Kim, Shinsuke Ito, Chen Yang, Pu Wang, Meng-Tao Xiao,[...]. Cancer Cell 2011
18

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.
Marina Konopleva, Daniel A Pollyea, Jalaja Potluri, Brenda Chyla, Leah Hogdal, Todd Busman, Evelyn McKeegan, Ahmed Hamed Salem, Ming Zhu, Justin L Ricker,[...]. Cancer Discov 2016
456
18

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.
Katharine Yen, Jeremy Travins, Fang Wang, Muriel D David, Erin Artin, Kimberly Straley, Anil Padyana, Stefan Gross, Byron DeLaBarre, Erica Tobin,[...]. Cancer Discov 2017
185
18

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
Hervé Dombret, John F Seymour, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James Cavenagh, Andre C Schuh, Anna Candoni,[...]. Blood 2015
564
17

Recurring mutations found by sequencing an acute myeloid leukemia genome.
Elaine R Mardis, Li Ding, David J Dooling, David E Larson, Michael D McLellan, Ken Chen, Daniel C Koboldt, Robert S Fulton, Kim D Delehaunty, Sean D McGrath,[...]. N Engl J Med 2009
17

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Patrick S Ward, Jay Patel, David R Wise, Omar Abdel-Wahab, Bryson D Bennett, Hilary A Coller, Justin R Cross, Valeria R Fantin, Cyrus V Hedvat, Alexander E Perl,[...]. Cancer Cell 2010
17

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.
Timothy J Ley, Christopher Miller, Li Ding, Benjamin J Raphael, Andrew J Mungall, A Gordon Robertson, Katherine Hoadley, Timothy J Triche, Peter W Laird, Jack D Baty,[...]. N Engl J Med 2013
16

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.
Daniel A Pollyea, Brett M Stevens, Courtney L Jones, Amanda Winters, Shanshan Pei, Mohammad Minhajuddin, Angelo D'Alessandro, Rachel Culp-Hill, Kent A Riemondy, Austin E Gillen,[...]. Nat Med 2018
222
16

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Eytan M Stein, Courtney D DiNardo, Amir T Fathi, Daniel A Pollyea, Richard M Stone, Jessica K Altman, Gail J Roboz, Manish R Patel, Robert Collins, Ian W Flinn,[...]. Blood 2019
133
16

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Lenny Dang, David W White, Stefan Gross, Bryson D Bennett, Mark A Bittinger, Edward M Driggers, Valeria R Fantin, Hyun Gyung Jang, Shengfang Jin, Marie C Keenan,[...]. Nature 2009
15

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Andrew M Intlekofer, Alan H Shih, Bo Wang, Abbas Nazir, Ariën S Rustenburg, Steven K Albanese, Minal Patel, Christopher Famulare, Fabian M Correa, Naofumi Takemoto,[...]. Nature 2018
108
15

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
Hagop M Kantarjian, Xavier G Thomas, Anna Dmoszynska, Agnieszka Wierzbowska, Grzegorz Mazur, Jiri Mayer, Jyh-Pyng Gau, Wen-Chien Chou, Rena Buckstein, Jaroslav Cermak,[...]. J Clin Oncol 2012
679
15

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Andrew H Wei, Stephen A Strickland, Jing-Zhou Hou, Walter Fiedler, Tara L Lin, Roland B Walter, Anoop Enjeti, Ing Soo Tiong, Michael Savona, Sangmin Lee,[...]. J Clin Oncol 2019
248
15

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Jeffrey E Lancet, Geoffrey L Uy, Jorge E Cortes, Laura F Newell, Tara L Lin, Ellen K Ritchie, Robert K Stuart, Stephen A Strickland, Donna Hogge, Scott R Solomon,[...]. J Clin Oncol 2018
314
14

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
Daniel A Pollyea, Martin S Tallman, Stéphane de Botton, Hagop M Kantarjian, Robert Collins, Anthony S Stein, Mark G Frattini, Qiang Xu, Alessandra Tosolini, Wendy L See,[...]. Leukemia 2019
66
21

IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Chao Lu, Patrick S Ward, Gurpreet S Kapoor, Dan Rohle, Sevin Turcan, Omar Abdel-Wahab, Christopher R Edwards, Raya Khanin, Maria E Figueroa, Ari Melnick,[...]. Nature 2012
13

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
Fang Wang, Jeremy Travins, Byron DeLaBarre, Virginie Penard-Lacronique, Stefanie Schalm, Erica Hansen, Kimberly Straley, Andrew Kernytsky, Wei Liu, Camelia Gliser,[...]. Science 2013
541
13

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Andrew H Wei, Pau Montesinos, Vladimir Ivanov, Courtney D DiNardo, Jan Novak, Kamel Laribi, Inho Kim, Don A Stevens, Walter Fiedler, Maria Pagoni,[...]. Blood 2020
107
13

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
Jorge E Cortes, Samer Khaled, Giovanni Martinelli, Alexander E Perl, Siddhartha Ganguly, Nigel Russell, Alwin Krämer, Hervé Dombret, Donna Hogge, Brian A Jonas,[...]. Lancet Oncol 2019
124
12

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Lynn Quek, Muriel D David, Alison Kennedy, Marlen Metzner, Michael Amatangelo, Alan Shih, Bilyana Stoilova, Cyril Quivoron, Maël Heiblig, Christophe Willekens,[...]. Nat Med 2018
73
15

Isocitrate dehydrogenase mutations in myeloid malignancies.
B C Medeiros, A T Fathi, C D DiNardo, D A Pollyea, S M Chan, R Swords. Leukemia 2017
170
11

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Gerrit J Schuurhuis, Michael Heuser, Sylvie Freeman, Marie-Christine Béné, Francesco Buccisano, Jacqueline Cloos, David Grimwade, Torsten Haferlach, Robert K Hills, Christopher S Hourigan,[...]. Blood 2018
390
11

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
Sung Choe, Hongfang Wang, Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Gail J Roboz, Jessica K Altman, Alice S Mims, Justin M Watts, Daniel A Pollyea,[...]. Blood Adv 2020
39
28

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Eytan M Stein, Courtney D DiNardo, Amir T Fathi, Alice S Mims, Keith W Pratz, Michael R Savona, Anthony S Stein, Richard M Stone, Eric S Winer, Christopher S Seet,[...]. Blood 2021
27
40

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Pierre Fenaux, Ghulam J Mufti, Eva Hellstrom-Lindberg, Valeria Santini, Carlo Finelli, Aristoteles Giagounidis, Robert Schoch, Norbert Gattermann, Guillermo Sanz, Alan List,[...]. Lancet Oncol 2009
10

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
Jay P Patel, Mithat Gönen, Maria E Figueroa, Hugo Fernandez, Zhuoxin Sun, Janis Racevskis, Pieter Van Vlierberghe, Igor Dolgalev, Sabrena Thomas, Olga Aminova,[...]. N Engl J Med 2012
10

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Hartmut Döhner, Elihu H Estey, Sergio Amadori, Frederick R Appelbaum, Thomas Büchner, Alan K Burnett, Hervé Dombret, Pierre Fenaux, David Grimwade, Richard A Larson,[...]. Blood 2010
10

Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
Amir T Fathi, Courtney D DiNardo, Irina Kline, Laurie Kenvin, Ira Gupta, Eyal C Attar, Eytan M Stein, Stephane de Botton. JAMA Oncol 2018
86
11

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Mojca Jongen-Lavrencic, Tim Grob, Diana Hanekamp, François G Kavelaars, Adil Al Hinai, Annelieke Zeilemaker, Claudia A J Erpelinck-Verschueren, Patrycja L Gradowska, Rosa Meijer, Jacqueline Cloos,[...]. N Engl J Med 2018
299
10

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.
Courtney D DiNardo, Farhad Ravandi, Sam Agresta, Marina Konopleva, Koichi Takahashi, Tapan Kadia, Mark Routbort, Keyur P Patel, Mark Brandt, Sherry Pierce,[...]. Am J Hematol 2015
147
10

Age and acute myeloid leukemia.
Frederick R Appelbaum, Holly Gundacker, David R Head, Marilyn L Slovak, Cheryl L Willman, John E Godwin, Jeanne E Anderson, Stephen H Petersdorf. Blood 2006
824
10

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Alexander E Perl, Jessica K Altman, Jorge Cortes, Catherine Smith, Mark Litzow, Maria R Baer, David Claxton, Harry P Erba, Stan Gill, Stuart Goldberg,[...]. Lancet Oncol 2017
257
10

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
Courtney D DiNardo, Keith W Pratz, Anthony Letai, Brian A Jonas, Andrew H Wei, Michael Thirman, Martha Arellano, Mark G Frattini, Hagop Kantarjian, Relja Popovic,[...]. Lancet Oncol 2018
297
10

Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.
James J Harding, Maeve A Lowery, Alan H Shih, Juan M Schvartzman, Shengqi Hou, Christopher Famulare, Minal Patel, Mikhail Roshal, Richard K Do, Ahmet Zehir,[...]. Cancer Discov 2018
56
17

IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009
9

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
Robert K Hills, Sylvie Castaigne, Frederick R Appelbaum, Jacques Delaunay, Stephen Petersdorf, Megan Othus, Elihu H Estey, Hervé Dombret, Sylvie Chevret, Norbert Ifrah,[...]. Lancet Oncol 2014
326
9

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
Courtney D DiNardo, Abhishek Maiti, Caitlin R Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval G Daver, Tapan M Kadia, Gautam Borthakur, Maro Ohanian, Yesid Alvarado,[...]. Lancet Haematol 2020
47
19

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics.
Danielle Golub, Nishanth Iyengar, Siddhant Dogra, Taylor Wong, Devin Bready, Karen Tang, Aram S Modrek, Dimitris G Placantonakis. Front Oncol 2019
91
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.